Respiratory Infections

Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.

Veterinary and public health officials share the important roles of surveillance and prevention strategies, insights on the virus's transmission pathways, historical context, the One Health approach, and highlights effective precautionary measures to mitigate H5N1 risks.

Reducing the age for pneumococcal vaccination allows more adults to safeguard themselves against pneumococcal disease during a period when their risk of infection significantly rises.

Without a specific tailored Long COVID therapy, individualized treatment based on patient phenotypes, along with extensive evaluations, is essential for effective symptom management.

David Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.

This new indication for the bivalent respiratory syncytial virus prefusion F vaccine (Abrysvo) makes it the broadest currently available.

Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.

Anushua Sinha, MD, discussed the findings, highlighting a 60.4% reduction in medically attended lower respiratory infections and significant decreases in RSV-related hospitalizations.

Invivyd’s Chief Scientific Officer Robert Allen, PhD, discusses the company’s pemivibart (Pemgarda) including its administration, how it can be used in concert with vaccines, and how it protects against newer variants.

The individuals are agricultural workers in Washington state who were in close proximity to and working with infected poultry at an egg farm.

Study results show that the vaccine elicits a comparable immune response in high-risk adults aged 18-59 with chronic medical conditions, suggesting potential for broader vaccination efforts.

With the approval of newer products, clinicians have tools to prevent the respiratory virus in the most vulnerable population. Helen Chu, MD, MPH, offers some insights on their efficacy and the nuances of the delivery of the 2 immunizations.

In our latest roundtable series, experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline.

At ID Week 2024, an investigator, Amanda M. Casto, MD, PhD, discusses her work on the CASCADIA study, which examined infection rates in this setting, and how it challenged assumptions that there is likely a singular carrier bringing viruses into homes.

The state's outbreak has reached over 100 confirmed cases among dairy herds, contributing to a national total of 300 outbreaks across 14 states.

In our latest roundtable series, the discussion addressed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.

A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.

Despite evidence of their effectiveness in reducing hospitalization and mortality rates, many older individuals remain untreated, with recent studies highlighting significant disparities in treatment access and adherence.

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus-related lower respiratory tract disease in older adults over three seasons.

People can now take the Healgen Rapid Check COVID-19/Flu A&B Antigen Test in their homes without a prescription.

Forty percent of the dose of the PCV 13 vaccine, but not of the PCV 10 or lower dose, was found noninferior to full doses when immunizing infants in Kenya.

Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.

Part 1 of James F Cummings, MD interview, discusses the trial's goals and highlights the vaccine's potential to generate mucosal immunity, its logistical advantages and ease of administration.

In part 1 of a 2-part story, an investigator discusses the use of procalcitonin and C-reactive protein guided protocols for community-acquired pneumonia (CAP).

Enanta Pharmaceuticals says its investigational therapy, EDP-323, was found to be safe and efficacious against the respiratory virus.

The Centers for Disease Control and Prevention (CDC) says a return to normalcy and vaccination protection waning are likely causes.

The CDC recommends vaccination for pregnant individuals and the administration of the RSV antibody nirsevimab to infants under eight months.

Study finds this population saw a 45% reduction of ongoing symptoms in those with COVID-19 weeks later and who had received subsequent doses of the original monovalent vaccine.

An English modeling study suggests level of protection decreases only very slightly over time and reminds parents to have their children up to date on all vaccinations.

The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.